ÿþ<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"> <html> <head> <meta http-equiv="Content-Type" content="text/html; charset=iso-8859-1"> <title>EASL 2010 - Poster Presentations</title> <link rel="stylesheet" type="text/css" href="style.css"> </head> <body> <table width="750" align="center" border="0" cellspacing="0" cellpadding="0" class="MainTable"> <tr> <td><img src="http://www2.kenes.com/liver-congress/PublishingImages/top_ei.jpg" width="760" height="129" /></td> </tr> <tr> <td class="content"><h1>Poster Presentations</h1> <P><b><u>Apr 15, 2010</u></b></P><p align=right><em>Poster Board Number</em></p><H2>Category 13. LATE-BREAKERS:<br /></H2><table><tr> <td><a href='Abstract1.htm'><B>PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF NITAZOXANIDE PLUS PEGINTERFERON AND RIBAVIRIN IN HCV GENOTYPE 1 NAïVE PATIENTS: WEEK 12 SUSTAINED VIROLOGIC RESPONSE RATE</B></a> </em><br> <b>B.R. Bacon</b><sup>1</sup>*, M.L. Shiffman<sup>2</sup>, J.K. Lim<sup>3</sup>, A. Berman<sup>4</sup>, V.K. Rustgi<sup>5</sup>, E.B. Keeffe<sup>6,7</sup><br> <em><sup>1</sup>Division of Gastroenterology and Hepatology, St Louis University Medical Center, St Louis, MO, <sup>2</sup>Liver Institute of Virginia, Bon Secours Health System, Newport News, VA, <sup>3</sup>Section of Digestive Diseases, Yale University School of Medicine, New Haven, CT, <sup>4</sup>Florida Center for Gastroenterology, Largo, FL, <sup>5</sup>Georgetown University Medical Center, Washington, DC, <sup>6</sup>The Romark Institute for Medical Research, Romark Laboratories, L.C., Sausalito, <sup>7</sup>Division of Gastroenterology and Hepatology, Stanford University Medical Center, Stanford, CA, USA. *baconbr@slu.edu</em></td><td valign=top><em>2001 </td></tr> <tr> <td><a href='Abstract2.htm'><B>SLC28A2 65C>T PREDICT SUSTAINED VIROLOGICAL RESPONSE IN PATIENTS WITH HEPATITIS C TREATED WITH INTERFERON AND RIBAVIRIN, CONSIDERING ALL HCV GENOTYPE AND GENOTYPE 1/4</B></a> </em><br> A. D'Avolio<sup>1</sup>, <b>A. Ciancio</b><sup>2</sup>*, M. Siccardi<sup>1</sup>, L. Baietto<sup>1</sup>, M. Simiele<sup>1</sup>, S. Patanella<sup>1</sup>, D. Aguilar Marucco<sup>1</sup>, G. Cariti<sup>1</sup>, A. Calcagno<sup>1</sup>, M. Sciandra<sup>1</sup>, A. Smedile<sup>2</sup>, F.G. De Rosa<sup>1</sup>, S. Bonora<sup>1</sup>, M. Rizzetto<sup>2</sup>, G. Di Perri<sup>1</sup><br> <em><sup>1</sup>Department of Infectious Diseases, <sup>2</sup>Department of GastroHepatology, University of Turin, Turin, Italy. *alessiaciancio@libero.it</em></td><td valign=top><em>2002 </td></tr> <tr> <td><a href='Abstract3.htm'><B>ANTIVIRAL ACTIVITY, PHARMACOKINETICS, AND TOLERABILITY OF AZD7295, A NOVEL NS5A INHIBITOR, IN A PLACEBO-CONTROLLED MULTIPLE ASCENDING DOSE STUDY IN HCV GENOTYPE 1 AND 3 PATIENTS</B></a> </em><br> <b>E. Gane</b><sup>1</sup>*, G.R. Foster<sup>2</sup>, J. Cianciara<sup>3</sup>, C. Stedman<sup>4</sup>, S. Ryder<sup>5</sup>, M. Buti<sup>6</sup>, E. Clark<sup>7</sup>, D. Tait<sup>7</sup><br> <em><sup>1</sup>Auckland City Hospital, Auckland, New Zealand, <sup>2</sup>Queen Mary University of London, The Royal London Hospital, London, UK, <sup>3</sup>Regional Hospital of Infectious Diseases, Warsaw, Poland, <sup>4</sup>Christchurch Clinical Studies, Christchurch, New Zealand, <sup>5</sup>Nottingham University Hospitals NHS Trust, Nottingham, UK, <sup>6</sup>Hospital Universitario Valle Hebron, Barcelona, Spain, <sup>7</sup>Arrow Therapeutics Ltd, London, UK. *edgane@adhb.govt.nz</em></td><td valign=top><em>2003 </td></tr> <tr> <td><a href='Abstract4.htm'><B>DETECTION OF MIXTURES OF HEPATITIS C VIRUS (HCV) TYPES</B></a> </em><br> <b>M. Holodniy</b><sup>1</sup>*, R.S. Diaz<sup>2</sup>, R.L. Mathis<sup>3</sup>, P.M. Feorino<sup>3</sup>, C. Loveday<sup>4</sup>, Z. Grossman<sup>5</sup>, R. Kantor<sup>6</sup>, Y.W. Tang<sup>7</sup>, R.M. Lloyd, Jr<sup>3</sup><br> <em><sup>1</sup>AIDS Research Center, VA Palo Alto Healthcare System, Palo Alto, CA, USA, <sup>2</sup>Retrovirology Laboratory, Federal University of São Paulo, São Paulo, Brazil, <sup>3</sup>CSO, Research Think Tank, Inc., Buford, GA, USA, <sup>4</sup>ICVC Charitable Trust HQ, Buckinghamshire, UK, <sup>5</sup>Clinical Virology Laboratory and National Reference Laboratory, Sheba Medical Center, Ramat Gan, Israel, <sup>6</sup>Division of Infectious Diseases, Brown University Medical School, Providence, RI, <sup>7</sup>Molecular Infectious Diseases Laboratory, Vanderbilt University Medical Center, Nashville, TN, USA. *mark.holodniy@med.va.gov</em></td><td valign=top><em>2004 </td></tr> <tr> <td><a href='Abstract5.htm'><B>VIROLOGIC RESPONSE RATES FOLLOWING 4 WEEKS OF FILIBUVIR IN COMBINATION WITH PEGYLATED INTERFERON ALFA-2A AND RIBAVIRIN IN CHRONICALLY-INFECTED HCV GENOTYPE-1 PATIENTS</B></a> </em><br> <b>I. Jacobson</b><sup>1</sup>*, P.J. Pockros<sup>2</sup>, J. Lalezari<sup>3</sup>, E. Lawitz<sup>4</sup>, M. Rodriguez-Torres<sup>5</sup>, E. DeJesus<sup>6</sup>, F. Haas<sup>7</sup>, C. Martorell<sup>8</sup>, R. Pruitt<sup>9</sup>, V. Purohit<sup>10</sup>, S. Srinivasan<sup>10</sup>, S. Jagannatha<sup>10</sup>, K. Rana<sup>10</sup>, J. Hammond<sup>10</sup><br> <em><sup>1</sup>Weill Cornell Medical College, New York, NY, <sup>2</sup>The Scripps Clinic, La Jolla, <sup>3</sup>Quest Clinical Research, San Francisco, CA, <sup>4</sup>Alamo Medical Research, San Antonio, TX, <sup>5</sup>Fundacion de Investigacion de Diego and Ponce School of Medicine, Santurce, PR, <sup>6</sup>Orlando Immunology Center, Orlando, FL, <sup>7</sup>University of Oklahoma-Schusterman Clinic, Tulsa, OK, <sup>8</sup>The Research Institute, Springfield, MA, <sup>9</sup>Nashville Medical Research Institute and Maria Nathanson Center of Excellence at Saint Thomas Hospital, Nashville, TN, <sup>10</sup>Specialty Care, Pfizer, New London, CT, USA. *imj2001@med.cornell.edu</em></td><td valign=top><em>2005 </td></tr> <tr> <td><a href='Abstract6.htm'><B>GI-5005 THERAPEUTIC VACCINE PLUS PEG-IFN/RIBAVIRIN SIGNIFICANTLY IMPROVES VIROLOGIC RESPONSE AND ALT NORMALIZATION AT END-OF-TREATMENT AND IMPROVES SVR24 COMPARED TO PEG-IFN/RIBAVIRIN IN GENOTYPE-1 CHRONIC HCV PATIENTS</B></a> </em><br> <b>I.M. Jacobson</b><sup>1</sup>*, J.G. McHutchison<sup>2</sup>, T.D. Boyer<sup>3</sup>, E.R. Schiff<sup>4</sup>, G.T. Everson<sup>5</sup>, P.J. Pockros<sup>6</sup>, R.M. Chasen<sup>7</sup>, J.M. Vierling<sup>8,9</sup>, E.J. Lawitz<sup>10</sup>, M. Kugelmas<sup>11,12</sup>, N.C. Tsai<sup>13</sup>, M.L. Shiffman<sup>14</sup>, R.J. Buynak<sup>15</sup>, A.M. Sheikh<sup>16</sup>, B. Armstrong<sup>17</sup>, T.C. Rodell<sup>18</sup>, D. Apelian<sup>18</sup><br> <em><sup>1</sup>Center for the Study of Hepatitis C, Weill Cornell Medical College, New York, NY, <sup>2</sup>Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, <sup>3</sup>Department of Medicine, University of Arizona College of Medicine, Tucson, AZ, <sup>4</sup>Center for Liver Diseases, University of Miami School of Medicine, Miami, FL, <sup>5</sup>Department of Medicine, University of Colorado Denver, Aurora, CO, <sup>6</sup>Scripps Clinic, La Jolla, CA, <sup>7</sup>Maryland Digestive Disease Research, Laurel, MD, <sup>8</sup>Department of Medicine and Surgery, Baylor College of Medicine, <sup>9</sup>St. Luke's Episcopal Hospital, Houston, <sup>10</sup>Alamo Medical Research, San Antonio, TX, <sup>11</sup>South Denver Gastroenterology, PC, <sup>12</sup>Center for Disease of the Liver and Pancreas, Swedish Medical Center, Englewood, CO, <sup>13</sup>University of Hawaii, Honolulu, HI, <sup>14</sup>Liver Institute of Virginia, Bon Secours Health System, Newport News, VA, <sup>15</sup>Northwest Indiana Center for Clinical Research, Valparaiso, IN, <sup>16</sup>Gastrointestinal Specialists of Georgia, Marietta, GA, <sup>17</sup>QST Consultations, LTD, Allendale, MI, <sup>18</sup>GlobeImmune, Inc., Louisville, CO, USA. *imj2001@med.cornell.edu</em></td><td valign=top><em>2006 </td></tr> <tr> <td><a href='Abstract7.htm'><B>4 WEEK THERAPY WITH THE NON-NUCLEOSIDIC POLYMERASE INHIBITOR BI207127 IN COMBINATION WITH PEGINTERFERON-ALFA2A AND RIBAVIRIN IN TREATMENT NAïVE AND TREATMENT EXPERIENCED CHRONIC HCV GT1 PATIENTS</B></a> </em><br> <b>D. Larrey</b><sup>1</sup>*, A. Lohse<sup>2</sup>, V. de Ledinghen<sup>3</sup>, C. Trepo<sup>4</sup>, T. Gerlach<sup>5</sup>, J.-P. Zarski<sup>6</sup>, A. Tran<sup>7</sup>, P. Mathurin<sup>8</sup>, R. Thimme<sup>9</sup>, K. Arastéh<sup>10</sup>, C. Trautwein<sup>11</sup>, A. Cerny<sup>12</sup>, N. Dikopoulos<sup>13</sup>, M. Schuchmann<sup>14</sup>, M.H. Heim<sup>15</sup>, G. Gerken<sup>16</sup>, J. Stern<sup>17</sup>, K. Wu<sup>17</sup>, N. Abdallah<sup>18</sup>, B. Girlich<sup>19</sup>, S. Josepf<sup>17</sup>, B. Wulf<sup>20</sup>, F. Berger<sup>21</sup>, J. Steffgen<sup>20</sup>, BI207127 Study Group<br> <em><sup>1</sup>Hepato-Gastro-Enterology and transplantation service, Hôpital Saint Eloi, Montpellier, France, <sup>2</sup>Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany, <sup>3</sup>CHU de Bordeaux Hôpital Haut-Levêque Pessac, Bordeaux, <sup>4</sup>Hotel Dieu Hospital, Lyon, France, <sup>5</sup>Kantonsspital, St. Gallen, Switzerland, <sup>6</sup>CHU de Grenoble Hôpital A Michallon, Grenoble, <sup>7</sup>Hôpital Archet, Nice, <sup>8</sup>Hôpital Claude Huriez, Lille, France, <sup>9</sup>Medizinische Universitätsklinik Freiburg, Freiburg im Breisgau, <sup>10</sup>EPIMED GmbH Berlin, Berlin, <sup>11</sup>Universitätsklinikum Aachen, Aachen, Germany, <sup>12</sup>Clinica Luganese Moncucco, Lugano, Switzerland, <sup>13</sup>Universitätsklinik Ulm, Ulm, <sup>14</sup>Universitätsmedizin Mainz, Mainz, Germany, <sup>15</sup>Universitätsspital Basel, Basel, Switzerland, <sup>16</sup>Medizinische Universitätsklinik Essen, Essen, Germany, <sup>17</sup>Boehringer Ingelheim, Ridgefield, CT, USA, <sup>18</sup>Boehringer Ingelheim, Reims, France, <sup>19</sup>Boehringer Ingelheim, Basel, Switzerland, <sup>20</sup>Boehringer Ingelheim, Biberach, <sup>21</sup>Boehringer Ingelheim, Ingelheim, Germany. *dom-larrey@chu-montpellier.fr</em></td><td valign=top><em>2007 </td></tr> <tr> <td><a href='Abstract8.htm'><B>DOSE-RANGING, THREE-DAY MONOTHERAPY STUDY OF THE HCV NS3 PROTEASE INHIBITOR GS-9256</B></a> </em><br> <b>E.J. Lawitz</b><sup>1</sup>*, T.C. Marbury<sup>2</sup>, B.D. Vince<sup>3</sup>, N. Grunenberg<sup>4</sup>, M. Rodriguez-Torres<sup>5</sup>, M.P. De Micco<sup>6</sup>, J.N. Tarro<sup>7</sup>, M.J. Shelton<sup>8</sup>, S. West<sup>8</sup>, J. Zong<sup>8</sup>, A. Bae<sup>8</sup>, K. Wong<sup>9</sup>, H.-M. Mo<sup>9</sup>, D. Oldach<sup>8</sup>, W. Delaney<sup>9</sup>, F. Rousseau<sup>8</sup><br> <em><sup>1</sup>Alamo Medical Research, San Antonio, TX, <sup>2</sup>Orlando Clinical Research Center, Orlando, FL, <sup>3</sup>Vince & Associates Clinical Research, Inc., Overland Park, KS, <sup>4</sup>Charles River Clinical Services Northwest, Tacoma, WA, USA, <sup>5</sup>Fundacion De Investigacion De Diego, Santurce, Puerto Rico, <sup>6</sup>Advanced Clinical Research Institute, Anaheim, CA, <sup>7</sup>Columbia Research Group, Portland, OR, <sup>8</sup>Gilead Sciences, Inc, Durham, NC, <sup>9</sup>Gilead Sciences, Inc, Foster City, CA, USA. *lawitz@alamomedicalresearch.com</em></td><td valign=top><em>2008 </td></tr> <tr> <td><a href='Abstract9.htm'><B>SAFETY AND ANTIVIRAL ACTIVITY OF ANA598 IN COMBINATION WITH PEGYLATED INTERFERON ±2A PLUS RIBAVIRIN IN TREATMENT-NAÏVE GENOTYPE-1 CHRONIC HCV PATIENTS</B></a> </em><br> <b>E. Lawitz</b><sup>1</sup>*, M. Rodriquez-Torres<sup>2</sup>, V.K. Rustgi<sup>3</sup>, T. Hassanein<sup>4</sup>, M.H. Rahimy<sup>5</sup>, C.A. Crowley<sup>5</sup>, J.L. Freddo<sup>5</sup>, A. Muir<sup>6</sup>, J. McHutchison<sup>6</sup><br> <em><sup>1</sup>Alamo Medical Research, San Antonio, TX, <sup>2</sup>Fundación de Investigación de Diego, Santurce, PR, <sup>3</sup>Metropolitan Research, Fairfax, VA, <sup>4</sup>SCTI Research Foundation, Liver Center, San Clemente, <sup>5</sup>Anadys Pharmaceuticals, Inc, San Diego, CA, <sup>6</sup>Duke Clinical Research Institute, Durham, NC, USA. *lawitz@alamomedicalresearch.com</em></td><td valign=top><em>2009 </td></tr> <tr> <td><a href='Abstract10.htm'><B>Q2WEEK CONTROLLED-RELEASE-INTERFERON-ALPHA2B+RIBAVRIN REDUCES FLU-LIKE SYMPTOMS >50% AND PROVIDES EQUIVALENT EFFICACY IN COMPARISON TO WEEKLY PEGYLATED-INTERFERON-ALPHA2B+RIBAVIRIN IN TREATMENT-NAÏVE-GENOTYPE-1-CHRONIC-HEPATITIS-C: RESULTS FROM EMPOWER, A RANDOMIZED-OPEN-LABEL-12-WEEK-COMPARISON IN 133 PATIENTS</B></a> </em><br> <b>W.A. Long</b><sup>1</sup>*, D. Takov<sup>2</sup>, K. Tchernev<sup>3</sup>, I. Kotzev<sup>4</sup>, A. Rigney<sup>1</sup>, Z. Krastev<sup>5</sup>, S. Stoynov<sup>6</sup>, R. Balabanska<sup>7</sup>, E. Lawitz<sup>8</sup>, Z. Younossi<sup>9</sup>, R. Ghalib<sup>10</sup>, E. Zuckerman<sup>11</sup>, R. Safadi<sup>12</sup>, R. Tur-Kaspa<sup>13</sup>, N. Assy<sup>14</sup>, Y. Lurie<sup>15</sup><br> <em><sup>1</sup>Biolex Therapeutics, Pittsboro, NC, USA, <sup>2</sup>Military Medical Academy, <sup>3</sup>UMHAT  Alexandrovska , Sofia, <sup>4</sup>UMHAT  St. Marina , Varna, <sup>5</sup>UMHAT  St. Ivan Rilski , <sup>6</sup>UMHAT 'Queen Giovanna - ISUL' EAD, <sup>7</sup>Tokuda Hospital, Sofia, Bulgaria, <sup>8</sup>Alamo Medical Research, San Antonio, TX, <sup>9</sup>Inova Health Systems, Falls Church, VA, <sup>10</sup>The Liver Institute at Methodist Dallas, Dallas, TX, USA, <sup>11</sup>Carmel Medical Center,, Haifa, <sup>12</sup>Holy Family Hospital Nazareth, Nazareth, <sup>13</sup>Rabin Medical Center, Petah-Tikva, <sup>14</sup>Rebekah Ziv Medical Center, Zefat, <sup>15</sup>Sourasky Medical Center, Tel Aviv, Israel. *wlong@biolex.com</em></td><td valign=top><em>2010 </td></tr> <tr> <td><a href='Abstract11.htm'><B>IL28B POLYMORPHISM IS SIGNIFICANTLY CORRELATED WITH IFN ANTI-VIRAL EFFECTIVENESS ALREADY ON FIRST DAY OF PEGYLATED INTERFERON-A AND RIBAVIRIN THERAPY OF CHRONIC HCV INFECTION</B></a> </em><br> <b>A. Neumann</b><sup>1</sup>*, S. Bibert<sup>2</sup>, B. Haagmans<sup>3</sup>, A. Soulier<sup>4</sup>, F. Negro<sup>5</sup>, M. Lagging<sup>6</sup>, C. Ferrari<sup>7</sup>, S. Zeuzem<sup>8</sup>, J.-M. Pawlotsky<sup>4</sup>, S. Schalm<sup>3</sup>, P.-Y. Bochud<sup>2</sup>, DITTO-HCV group<br> <em><sup>1</sup>Faculty of Life Sciences, Bar-Ilan University, Ramat-Gan, Israel, <sup>2</sup>Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland, <sup>3</sup>Erasmus Medical Center, Rotterdam, The Netherlands, <sup>4</sup>Hopital Henri Mondor - Universite Paris XII, Creteil, France, <sup>5</sup>Hospital University of Geneve, Geneve, Switzerland, <sup>6</sup>University of Goeteborg, Goetoborg, Sweden, <sup>7</sup>Azienda Ospedaliera di Parma, Parma, Italy, <sup>8</sup>University of Frankfurt, Frankfurt, Germany. *neumann@mail.biu.ac.il</em></td><td valign=top><em>2011 </td></tr> <tr> <td><a href='Abstract12.htm'><B>VIROLOGICAL RESPONSE, SAFETY, AND PHARMACOKINETIC PROFILE FOLLOWING SINGLE- AND MULTIPLE-DOSE ADMINISTRATION OF ACH-0141625 PROTEASE INHIBITOR TO HEALTHY VOLUNTEERS AND HCV GENOTYPE-1 PATIENTS</B></a> </em><br> V. Detishin<sup>1</sup>, W. Haazen<sup>2</sup>, H. Robison<sup>3</sup>, L. Robarge<sup>3</sup>, <b>E. Olek</b><sup>3</sup>*<br> <em><sup>1</sup>Clinical Hospital of Infectious Diseases and, INNOPHAR MO S.R.L., Chisnau, Moldova, <sup>2</sup>SGS Life Science Services, Antwerpen, Belgium, <sup>3</sup>Achillion Pharmaceuticals, Inc., New Haven, CT, USA. *eolek@achillion.com</em></td><td valign=top><em>2012 </td></tr> <tr> <td><a href='Abstract13.htm'><B>ANTIVIRAL ACTIVITY, PHARMACOKINETICS AND SAFETY OF IDX184 IN COMBINATION WITH PEGYLATED INTERFERON (PEGIFN) AND RIBAVIRIN (RBV) IN TREATMENT-NAïVE HCV GENOTYPE 1-INFECTED SUBJECTS</B></a> </em><br> J. Lalezari<sup>1</sup>, <b>F. Poordad</b><sup>2</sup>*, P. Mehra<sup>3</sup>, T. Nguyen<sup>4</sup>, E. Dejesus<sup>5</sup>, E. Godofsky<sup>6</sup>, G. Dubuc Patrick<sup>7</sup>, J. Chen<sup>7</sup>, K. Pietropaolo<sup>7</sup>, X.-J. Zhou<sup>7</sup>, J.Z. Sullivan-Bólyai<sup>7</sup>, D. Mayers<sup>7</sup>, IDX-08C-004 Investigator Group<br> <em><sup>1</sup>Quest Clinical Research, San Francisco, <sup>2</sup>Cedars-Sinai Medical Center, Los Angeles, <sup>3</sup>eStudySite, <sup>4</sup>Tuan Trong Nguyen, MD, San Diego, CA, <sup>5</sup>Orlando Immunology Center, Orlando, <sup>6</sup>University Hepatitis Center at Bach & Godofsky, M.D., P.A., Sarasota, FL, <sup>7</sup>Idenix Pharmaceuticals, Inc., Cambridge, MA, USA. *fred.poordad@cshs.org</em></td><td valign=top><em>2013 </td></tr> <tr> <td><a href='Abstract14.htm'><B>IMPROVED INFLAMMATORY ACTIVITY WITH LOW-DOSE PEGINTRON (PEG) MAINTENANCE THERAPY IN PRIOR NONRESPONDERS WITH METAVIR FIBROSIS SCORES (MFS) OF F2/F3: FINAL RESULTS FROM THE EPIC<SUP>3</SUP> PROGRAM</B></a> </em><br> <b>T. Poynard</b><sup>1</sup>*, J. Bruix<sup>2</sup>, E. Schiff<sup>3</sup>, M. Diago<sup>4</sup>, T. Berg<sup>5</sup>, R. Moreno-Otero<sup>6</sup>, L.G. Lyra<sup>7</sup>, F.J. Carrilho<sup>8</sup>, N. Boparai<sup>9</sup>, L. Griffel<sup>10</sup>, M. Burroughs<sup>9</sup>, C. Brass<sup>9</sup>, J.K. Albrecht<sup>9</sup><br> <em><sup>1</sup>Service d'Hepato-Gastroenterologie, APHP-UPMC Liver Center, Paris, France, <sup>2</sup>Centro de Investigación Biomédica en Red de Enfermedades Hepaticas y Digestivas, Liver Unit, Hospital Clinic, University of Barcelona, Barcelona, Spain, <sup>3</sup>University of Miami School of Medicine, Miami, FL, USA, <sup>4</sup>Hospital General Universitario de Valencia, Valencia, Spain, <sup>5</sup>Charité, Campus Virchow Klinikum, Universitätsmedizin Berlin, Berlin, Germany, <sup>6</sup>Hospital Universitario de la Princesa and Centro de Investigación Biomédica en Red de Enfermedades Hepaticas y Digestivas (Instituto de Salud Carlos III), Madrid, Spain, <sup>7</sup>Hospital Sao Rafael, Salvador, <sup>8</sup>Gastroenterology, University of Sao Paulo School of Medicine, Sao Paulo, Brazil, <sup>9</sup>Schering-Plough Corporation, now Merck & Co., Inc., <sup>10</sup>Former employee of Schering-Plough Corporation, now Merck & Co., Inc., Whitehouse Station, NJ, USA. *tpoynard@teaser.fr</em></td><td valign=top><em>2014 </td></tr> <tr> <td><a href='Abstract15.htm'><B>GENOME WIDE ANALYSIS OF PATIENTS FROM THE IDEAL STUDY IDENTIFIES A CAUSAL ROLE FOR ITPA GENETIC VARIATION IN RIBAVIRIN-INDUCED HEMOLYTIC ANEMIA </B></a> </em><br> <b>A.J. Thompson</b><sup>1</sup>*, J. Fellay<sup>2</sup>, D. Ge<sup>2</sup>, T. Urban<sup>2</sup>, K. Shianna<sup>2</sup>, M. Sulkowski<sup>3</sup>, A. Muir<sup>1</sup>, N. Afdhal<sup>4</sup>, I. Jacobson<sup>5</sup>, R. Esteban<sup>6</sup>, F. Poordad<sup>7</sup>, E. Lawitz<sup>8</sup>, J. Mc Cone<sup>9</sup>, M. Shiffman<sup>10</sup>, G. Galler<sup>11</sup>, W. Lee<sup>12</sup>, R. Reindollar<sup>13</sup>, J. King<sup>14</sup>, P. Kwo<sup>15</sup>, R. Ghalib<sup>16</sup>, B. Freilich<sup>17</sup>, L. Nyberg<sup>18</sup>, K. Patel<sup>1</sup>, H. Tillmann<sup>1</sup>, S. Noviello<sup>19</sup>, N. Bopari<sup>19</sup>, K. Koury<sup>19</sup>, L. Pedicone<sup>19</sup>, C. Brass<sup>19</sup>, J.K. Albrecht<sup>19</sup>, D. Goldstein<sup>2</sup>, J.G. Mc Hutchison<sup>1</sup><br> <em><sup>1</sup>Duke Clinical Research Institute, <sup>2</sup>Institute for Genome Sciences & Policy, Center for Human Genome Variation, Duke University, Durham, NC, <sup>3</sup>Johns Hopkins University School of Medicine,, Baltimore, MD, <sup>4</sup>Beth Israel Deaconess Medical Centre, Boston, MA, <sup>5</sup>Weill Cornell Medical College, New York, NY, USA, <sup>6</sup>Hospital General Universitario Valle de Hebron, Barcelona, Spain, <sup>7</sup>Cedars-Sinai Medical Center, Los Angeles, CA, <sup>8</sup>Alamo Medical Research, San Antonio, TX, <sup>9</sup>Mt. Vernon Endoscopy Center, Alexandria, <sup>10</sup>Virginia Commonwealth University, Richmond, VA, <sup>11</sup>Kelsey Research Foundation, Houston, <sup>12</sup>University of Texas Southwestern Medical Center, Dallas, TX, <sup>13</sup>Piedmont Healthcare, Statesville, NC, <sup>14</sup>Louisiana State University, Shreveport, LA, <sup>15</sup>Indiana University School of Medicine, Indianapolis, IN, <sup>16</sup>The Liver Institute at Methodist Dallas Medical Center, Dallas, TX, <sup>17</sup>Kansas City Gastroenterology and Hepatology, Kansas City, MO, <sup>18</sup>Kaiser Permanente, San Diego, CA, <sup>19</sup>Schering-Plough Corporation (now Merck & Co., Inc.), Whitehouse Station, NJ, USA. *alexander.thompson@duke.edu</em></td><td valign=top><em>2015 </td></tr> <tr> <td><a href='Abstract16.htm'><B>LONG-TERM OUTCOMES FOLLOWING COMBINATION TREATMENT WITH BOCEPREVIR PLUS PEG-INTRON/RIBAVIRIN (P/R) IN PATIENTS WITH CHRONIC HEPATITIS C, GENOTYPE 1 (CHC-G1)</B></a> </em><br> <b>J.M. Vierling</b><sup>1</sup>*, R. Ralston<sup>2</sup>, E.J. Lawitz<sup>3</sup>, J. McCone<sup>4</sup>, S. Gordon<sup>5</sup>, D. Pound<sup>6</sup>, M. Davis<sup>7</sup>, J. Galati<sup>8</sup>, I. Jacobson<sup>9</sup>, L. Rossaro<sup>10</sup>, F.H. Anderson<sup>11</sup>, J. King<sup>12</sup>, W. Cassidy<sup>13</sup>, M. Bourliere<sup>14</sup>, R. Esteban-Mur<sup>15</sup>, N. Ravendhran<sup>16</sup>, G. Galler<sup>17</sup>, P. Mendez<sup>2</sup>, C.A. Brass<sup>2</sup>, J.K. Albrecht<sup>2</sup><br> <em><sup>1</sup>Advanced Liver Therapies/St. Luke's Episcopal Hospital, Houston, TX, <sup>2</sup>Merck Research Laboratories, Kenilworth, NJ, <sup>3</sup>Alamo Medical Research, San Antonio, TX, <sup>4</sup>Mount Vernon Endoscopy Center, Alexandria, VA, <sup>5</sup>Henry Ford Hospitals, Detroit, MI, <sup>6</sup>Indianapolis Gastroenterology Research Foundation, Indianapolis, IN, <sup>7</sup>South Florida Center of Gastroenterology, Wellington, FL, <sup>8</sup>Liver Specialists of Texas, Houston, TX, <sup>9</sup>Weill Medical College of Cornell University, New York, NY, <sup>10</sup>Davis Medical Center, University of California, Sacramento, CA, USA, <sup>11</sup>The Liver and Intestinal Research Centre, Vancouver, BC, Canada, <sup>12</sup>LSU Medical Center; Louisiana State University, Shreveport, <sup>13</sup>Louisiana State University, Baton Rouge, LA, USA, <sup>14</sup>Hospital Saint Joseph, Marseille Cedex, France, <sup>15</sup>Hospital Vall d'Hebron, Barcelona, Spain, <sup>16</sup>Digestive Disease Associates, Baltimore, MD, <sup>17</sup>Kelsey Research Foundation, Houston, TX, USA. *vierling@bcm.tmc.edu</em></td><td valign=top><em>2016 </td></tr> </table><a href='index.asp'>Back</a><br> <p>&nbsp;</p> <p>&nbsp;</p></td> </tr> </table> </body> </html>